ClinicalTrials.gg
TerminatedNCT00251095Updated Jun 4, 2009

Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer

A Phase 3 interventional study of Taxol and TOCOSOL Paclitaxel in Breast Neoplasm, sponsored by Achieve Life Sciences. Terminated at 14 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-04.

Sponsored by Achieve Life Sciences · Phase 3, Interventional, and Treatment

Why this study was terminated
Failed primary endpoint

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
821
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.

Enrollment
27th of 361
821 · median 60
Started
2005
with 16 others
Phase 3
61 of 373
6 open now
Registered
74th of 373
by date

Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 27th largest by enrollment of the 361 interventional ones that give a count, is one of 17 that started in 2005, is one of 61 in phase 3, and was the 74th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

35 more — sign in →

By country, each count listing its studies:

All 40 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies testing paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection) administered every week to patients with metastatic breast cancer. The study hypothesis is that the objective response rate with TOCOSOL Paclitaxel given every week is non-inferior to that observed with Taxol given every week.

Read the detailed description

Female patients with first or second line metastatic breast cancer will be randomized to receive either weekly TOCOSOL Paclitaxel or weekly Taxol (paclitaxel injection). Patients will undergo radiographic imaging of their disease to assess response to therapy. The primary endpoint of this study is a comparison of the objective response rates observed in patients receiving TOCOSOL Paclitaxel, to those receiving Taxol. Time-to-disease progression and overall survival will also be compared. The toxicities of the two treatment regimens will be compared.

03

Conditions studied

  • Breast Neoplasm

Browse trials for

Keywords

  • Metastatic Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with histologic diagnosis of breast carcinoma
  • Stage IV (M1) disease
  • Adult (18 years of age or older) patients

Exclusion criteria

Exclusion Criteria:

  • Patients treated with a taxane within the past year
  • Patients whose tumor tissue is known to show over expression of /neu
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
821 participants (actual)

Study arms

  • Active comparator
    Taxol

    Taxol 80mg/m2/week

    Drug: Taxol

  • Experimental
    TOCOSOL

    TOCOSOL Paclitaxel

    Drug: TOCOSOL Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rates

    Time frame: Based on enrollment

  2. Toxicities

    Time frame: Based on enrollment

Secondary outcomes

  1. Median overall survival

    Time frame: Based on enrollment

  2. Progression-free survival

    Time frame: Based on enrollment

  3. Time-to-disease progression

    Time frame: Based on enrollment

07

Study locations

14 sites
  • Alta Bates Comprehensive Cancer Center
    Berkeley, California 94704, United States
  • Desert Hematology Oncology Medical Group
    Rancho Mirage, California 92270, United States
  • Stockton Hematology Oncology
    Stockton, California 95204, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Mountain State Tumor Institute
    Boise, Idaho 83712, United States
  • Southfield Oncology Institute, Inc
    Southfield, Michigan 48076, United States
  • Oncology Care Associates
    St Joseph, Michigan 49085, United States
  • Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Essex Oncology of North Jersey
    Belleville, New Jersey 07109, United States
  • Mid Dakota Clinic
    Bismarck, North Dakota 58501, United States
  • Hematology Oncology Consultants, Inc
    Columbus, Ohio 43235, United States
  • Chattanooga Oncology & Hematology Associates, PC
    Chattanooga, Tennessee 37404, United States
  • The Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Joe Arrington Cancer Research and Treatment Center
    Lubbock, Texas 79410, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2005
First posted
Nov 9, 2005
Start
Sep 2005
Primary completionActual
Sep 2007
CompletionActual
Sep 2007
Last update
Jun 4, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00251095
First posted
Nov 9, 2005
Start date
Sep 2005
Primary completion
Sep 2007
Completion
Sep 2007
Last update
Jun 4, 2009
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion